Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Dec;70(12):3501-3511.
doi: 10.1007/s00262-021-02941-4. Epub 2021 Apr 25.

CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease

Wenyi Lu  1   2 , Yunxiong Wei  1 , Yaqing Cao  1 , Xia Xiao  1   2 , Qing Li  1   2 , Hairong Lyu  1   2 , Yili Jiang  1   2 , Huan Zhang  1   2 , Xin Li  1   2 , Yanyu Jiang  1   2 , Juanxia Meng  1   2 , Ting Yuan  1   2 , Haibo Zhu  1   2 , Xiaoyuan He  2 , Xin Jin  3 , Rui Sun  1 , Tao Sui  1   2 , Kaiqi Liu  4 , Mingfeng Zhao  5   6
Affiliations
Clinical Trial

CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease

Wenyi Lu et al. Cancer Immunol Immunother. 2021 Dec.

Abstract

The persistence or recurrence of minimal residual disease (MRD) after chemotherapy predicts relapse of B-cell acute lymphoblastic leukemia (B-ALL). CD19-directed chimeric antigen receptor T (CD19 CAR-T) cells have shown promising responses in B-ALL. However, their role in chemotherapy-refractory MRD-positive B-ALL remains unclear. Here we aimed to assess the effectiveness and safety of CD19 CAR-T cells in MRD-positive B-ALL patients. From January 2018, a total of 14 MRD-positive B-ALL patients received one or more infusions of autogenous CD19 CAR-T cells. Among them, 12 patients achieved MRD-negative remission after one cycle of CAR-T infusion. At a median follow-up time of 647 days (range 172-945 days), the 2-year event-free survival rate in MRD-positive patients was 61.2% ± 14.0% and the 2-year overall survival was 78.6 ± 11.0%, which were significantly higher than patients with active disease (blasts ≥ 5% or with extramedullary disease). Moreover, patients with MRD had a lower grade of cytokine release syndrome (CRS) than patients with active disease. However, the peak expansion of CAR-T cells in MRD positive patients showed no statistical difference compared to patients with active disease. Five patients received two or more CAR-T cell infusions and these patients showed a decreased peak expansion of CAR-T cell in subsequent infusions. In conclusion, pre-emptive CD19 CAR-T cell treatment is an effective and safe approach and may confer sustained remission in B-ALL patients with chemotherapy-refractory MRD. The trials were registered at www.chictr.org.cn as ChiCTR-ONN-16009862 (November 14, 2016) and ChiCTR1800015164 (March 11, 2018).

Keywords: B-cell acute lymphoblastic leukemia; CD19-directed chimeric antigen receptor T cells; Cytokine release syndrome; Minimal residual disease; Relapse.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interests.

Figures

Fig. 1
Fig. 1
The probability of two-year overall survival and event-free survival in MRD-positive patients and the patients with active disease treated after CAR-T cell therapy. a The probability of two-year overall survival after CAR-T cell therapy; b The probability of two-year event-free survival after CAR-T cell therapy
Fig. 2
Fig. 2
Comparison of cytokine release and CAR-T cell proliferation between MRD-positive patients and the patients with active disease after CAR-T cell infusion. a The incidence of CRS of all grades after CAR-T cell therapy in MRD-positive B-ALL patients (n = 14) and the patients with active disease (n = 29). b–g The peak levels of serum CRP, IL-2, IL-6, IL-8, IL-10 and ferritin in MRD-positive B-ALL patients (n = 14) or the patients with active disease (n = 29); h The peak level of CD19 CAR-T cells in peripheral blood after CAR-T cell infusion
Fig. 3
Fig. 3
Proliferation of CAR-T cells after repeated infusion. a The proliferation and persistence of CAR-T cells after the second infusion; b The peak expansion of CAR-T cells after each infusion
See this image and copyright information in PMC

References

    1. Bassan R, Bruggemann M, Radcliffe HS, Hartfield E, Kreuzbauer G, Wetten S. A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia. Haematologica. 2019;104(10):2028–2039. doi: 10.3324/haematol.2018.201053. - DOI - PMC - PubMed
    1. Raff T, Gokbuget N, Luschen S, Reutzel R, Ritgen M, Irmer S, Bottcher S, Horst HA, Kneba M, Hoelzer D, Bruggemann M, Group GS Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood. 2007;109(3):910–915. doi: 10.1182/blood-2006-07-037093. - DOI - PubMed
    1. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–1518. doi: 10.1056/NEJMoa1215134. - DOI - PMC - PubMed
    1. Davila ML, Brentjens RJ. CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2016;14(10):802–808. - PMC - PubMed
    1. He X, Xiao X, Li Q, Jiang Y, Cao Y, Sun R, Jin X, Yuan T, Meng J, Ma L, Lu W, Lyu C, Liu K, Zhao M. Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL [letter] Leukemia. 2019;33(8):2102–2104. doi: 10.1038/s41375-019-0437-5. - DOI - PMC - PubMed

Publication types

LinkOut - more resources